Clinical Trials
Dexketoprofen Trometamol Plus Sufentanil PCIA After Thoracoscopic Lung Resection
Guo et alDrug Design, Development, and Therapy

In a randomized, double-blind, placebo-controlled trial, investigators evaluated whether adding dexketoprofen trometamol to sufentanil-based patient-controlled intravenous analgesia (PCIA) reduces 48-hour opioid requirements and improves postoperative pain outcomes following thoracoscopic radical resection of lung cancer. A total of 108 patients were randomized preoperatively (54 per group). Following 18 post-randomization exclusions prior to PCIA initiation, 45 patients per arm were included in the final analysis. All participants underwent unilateral uniportal anatomical segmentectomy with mediastinal lymph node dissection or sampling and received a standardized intercostal nerve block, receiving either sufentanil-based PCIA alone (Group S) or sufentanil combined with dexketoprofen trometamol (Group R).
The primary outcome of total 48-hour postoperative sufentanil consumption (including rescue doses) was significantly lower in Group R than in Group S (78.03 ± 10.66 vs 96.78 ± 13.69 μg; mean reduction of 18.75 μg, 95% CI 13.61 to 23.89; P < 0.001), reflecting an approximate 19% reduction in opioid use. Resting pain scores demonstrated significant reductions in the dexketoprofen group at 12 and 24 hours (both P = 0.004), meeting the pre-specified Bonferroni-corrected threshold of P < 0.005 for multiple time points. However, the difference in coughing pain at 12 hours (P = 0.006) did not meet this significance threshold. While the area under the curve for resting pain was lower in the combination arm (P = 0.009), generalized estimating equations (GEE) identified no significant overall group effect or group-by-time interaction for resting or coughing pain.
Regarding safety and secondary outcomes, nausea occurred significantly less frequently among patients receiving dexketoprofen trometamol compared to controls (11.1% vs 28.9%; P = 0.035). The authors concluded that dexketoprofen trometamol effectively reduces 48-hour sufentanil consumption, but noted that pain score improvements were confined to specific time points rather than demonstrating sustained overall analgesic superiority. Additionally, the trial was not sufficiently powered to establish safety regarding uncommon adverse events.
Key Takeaways
- Adding dexketoprofen trometamol to sufentanil-based patient-controlled intravenous analgesia significantly reduced 48-hour postoperative sufentanil consumption by 18.75 μg (78.03 ± 10.66 vs 96.78 ± 13.69 μg; 95% CI 13.61 to 23.89; P < 0.001), representing an approximate 19% reduction.
- Postoperative nausea incidence was significantly lower in the dexketoprofen trometamol group compared with the control group (11.1% vs 28.9%; P = 0.035).
- Resting pain scores were significantly lower with dexketoprofen trometamol at 12 and 24 hours (both P = 0.004), although generalized estimating equations demonstrated no significant overall group effect or group-by-time interaction across the full postoperative period for resting or coughing pain.
Read the original sourceDrug Design, Development, and Therapy
